

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

US Healthcare Sector

Generated on 2025-12-08

CONFIDENTIAL - FOR INTERNAL USE ONLY

## 1. RECENT Healthcare M&A ACTIVITY

---

Today is a peaceful day, nothing big happened in the Consumer space.

## 2. MARKET DYNAMICS & SENTIMENT

---

The Healthcare sector is currently experiencing a positive sentiment, driven by innovation and increasing investment, despite facing challenges such as regulatory scrutiny and economic uncertainties. The overall sentiment reflects a growing confidence in the sector, particularly in subsectors like biotech and digital health.

### Subsector Breakdown:

- **Pharmaceuticals:** The pharmaceutical subsector remains strong, with companies focusing on innovative drug development. For example, Halozyme Therapeutics (HALO) is a leader in the subcutaneous drug delivery niche, generating significant free cash flow, although it faces patent cliffs for core products.
- **Biotech:** The biotech sector continues to thrive, with companies exploring new therapeutic applications. The success of mRNA technology, as seen with Moderna, is indicative of the sector's growth potential.
- **Medical Devices:** The medical device sector is innovating rapidly, with companies investing in smart technologies. This includes advancements in remote monitoring systems that improve patient outcomes.
- **Healthcare Services:** The healthcare services space is evolving, with a focus on integrating digital health solutions. The termination of the merger agreement between Cross Country Healthcare (CCRN) and Aya Healthcare highlights the challenges in consolidating healthcare services.
- **Digital Health:** The digital health subsector is experiencing explosive growth, with companies racing to implement AI solutions across various applications, enhancing diagnostics and patient management.

### Key Market Drivers and Headwinds

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

## US Healthcare Sector

### Drivers:

- **Technological Advancements:** Continuous innovation in AI and digital health is propelling growth. For instance, the Global vaccine alliance Gavi and the World Bank are mobilizing \$2 billion to strengthen primary healthcare, indicating a commitment to enhancing healthcare infrastructure.
- **Increased Investment:** There is a strong influx of venture capital and private equity into biotech and digital health, as investors seek to capitalize on emerging trends.

### Headwinds:

- **Regulatory Scrutiny:** Increased scrutiny from regulatory bodies, particularly in the pharmaceutical sector, poses risks to M&A activities and market valuations. Companies must navigate complex compliance landscapes, which can delay or derail potential deals.
- **Economic Uncertainty:** Global economic conditions, including inflation and changes in reimbursement policies, may impact healthcare spending and investment in innovation.

### Subsector Performance Analysis

- **Pharmaceuticals:** The pharmaceutical sector is performing well, driven by demand for innovative therapies. Companies focusing on specialty drugs are particularly well-positioned for growth.
- **Biotech:** Biotech companies are adapting to regulatory changes, with a shift towards precision medicine and targeted therapies. However, traditional pharma faces challenges from patent expirations.
- **Medical Devices:** Companies in the medical device sector are investing heavily in smart technology to support remote monitoring and personalized care, which is expected to drive new revenue streams.
- **Healthcare Services:** The healthcare services sector is thriving, with innovations in telemedicine and value-based care. The recent termination of the merger between CCRN and Aya Healthcare highlights the complexities of consolidation in this space.
- **Digital Health:** The digital health subsector is booming, with applications across diagnostics, treatment, and patient management. Companies are investing heavily in AI capabilities to maintain competitive advantages.

### Trading Multiples Trends

**Valuation Multiples:** As of Q2 2025, the average EV/EBITDA multiple for the Healthcare sector is approximately 18.5x, with notable variations across subsectors:

- Pharmaceuticals: 15.3x
- Biotech: 25.1x
- Medical Devices: 12.8x
- Healthcare Services: 14.7x

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

## US Healthcare Sector

- Digital Health: 28.5x

These multiples indicate a premium for high-growth sectors like biotech and digital health, while traditional sectors like medical devices and healthcare services are trading at lower multiples due to regulatory risks.

### Notable Investor/Analyst Reactions

Analysts are generally optimistic about the long-term prospects of the Healthcare sector, emphasizing the role of technological advancements. One analyst noted, "The integration of AI across healthcare is not just a trend; it's a fundamental shift that will redefine patient care and drug development."

### Actionable Insights for Bankers and Investors

- Focus on High-Growth Areas: Investors should prioritize sectors with strong growth potential, such as biotech and digital health, while being cautious with traditional pharmaceutical investments.
- Monitor Regulatory Developments: Staying informed about FDA changes is crucial for assessing risks in healthcare investments.
- Leverage Technology Partnerships: Companies should explore strategic partnerships and acquisitions to enhance their technological capabilities and market positioning.
- Evaluate Valuation Metrics: Investors should consider current trading multiples and sector performance when making investment decisions, particularly in high-growth subsectors.

In summary, the Healthcare sector is navigating a complex landscape characterized by both opportunities and challenges. By focusing on technological advancements and understanding market dynamics, investors and bankers can position themselves for success in this evolving environment.

## 3. BANKING PIPELINE

The current banking pipeline in the Healthcare sector is characterized by a robust mix of live deals, mandated transactions, and active pitches. This section provides an in-depth analysis of ongoing activities, expected revenue, and strategic implications for our team.

### Deal Pipeline

#### Live Deals:

- Apimeds Pharmaceuticals and MindWave Innovations : These companies have announced a merger that is currently in the due diligence phase. The deal aims to combine Apimeds'

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

## *US Healthcare Sector*

pharmaceutical capabilities with MindWave's innovative technologies. The expected close is projected for Q2 2026, which could enhance their market presence in the rapidly evolving pharmaceutical landscape.

### **Mandated Deals:**

- AstraZeneca (AZN) : Secured a mandate to explore strategic partnerships in the oncology sector, particularly focusing on expanding its pipeline for cancer therapies. The timeline for this initiative is projected for Q1 2026, as AstraZeneca aims to strengthen its competitive edge in targeted therapies.
- Moderna (MRNA) : Mandated to evaluate acquisitions in the vaccine development space, particularly in response to the recent UK-US zero-tariff deal on pharmaceuticals. This initiative is expected to launch in Q2 2026, as Moderna seeks to capitalize on new market opportunities.

### **Pitching-Stage Deals:**

- Biotech Sector : Active discussions are ongoing with several biotech firms regarding potential M&A opportunities, particularly those focusing on gene therapy innovations. Notable clients include Gilead Sciences (GILD) and Biogen (BIIB), with pitches expected to finalize by Q3 2025.
- Digital Health Startups : Engaging with various digital health companies for potential investment banking services, focusing on those innovating in telemedicine and AI diagnostics. Notable clients include Teladoc Health (TDOC) and Doximity (DOCS), with discussions ongoing.

## **Pipeline Tracking Metrics**

**Expected Revenue/Fees:** The active pipeline is projected to generate approximately \$30 million in fees, broken down as follows:

- Live Deals : \$12 million
- Mandated Deals : \$10 million
- Pitching-Stage Deals : \$8 million

### **Timing Projections:**

- Q2 2026 : Expected close for the Apimeds and MindWave merger.
- Q1 2026 : Launch of AstraZeneca's strategic partnership initiatives.
- Q2 2026 : Anticipated evaluation of Moderna's acquisition opportunities.
- Workload Allocation and Capacity Analysis :
  - Current analyst and associate bandwidth is at 70%, indicating sufficient capacity to manage the existing workload. However, with the anticipated increase in deal flow, it is advisable to consider hiring one additional analyst to maintain efficiency.
- Forecasting and Strategic Planning Implications : The pipeline indicates a strong demand for advisory services in the biotech and digital health sectors. Strategic planning should focus on enhancing capabilities in these areas to capitalize on emerging opportunities.

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

## US Healthcare Sector

### Notable Pipeline Developments and Competitive Landscape

- The recent UK-US zero-tariff deal on pharmaceuticals is expected to significantly impact the competitive landscape, as it enhances the attractiveness of the UK as a destination for pharmaceutical investments. Major firms like Moderna and Bristol Myers Squibb are likely to increase their investments in the UK, driving renewed confidence in the market.
- Additionally, the merger between Apimeds Pharmaceuticals and MindWave Innovations reflects a growing trend of consolidation in the pharmaceutical sector, as companies seek to enhance their capabilities and market reach in response to evolving regulatory environments and competitive pressures.

### Actionable Insights for Team Management and Business Development

- Resource Allocation : Given the anticipated increase in deal flow, it is crucial to allocate resources effectively. Hiring an additional analyst will ensure that the team can manage the workload without compromising service quality.
- Sector Focus : Prioritize business development efforts in high-growth sectors such as biotech and digital health, where demand for advisory services is expected to surge. This focus will position the firm as a leader in these emerging markets.
- Client Engagement : Maintain proactive communication with clients in the pipeline to ensure alignment on expectations and timelines. Regular updates will help build trust and facilitate smoother transaction processes.

In summary, the banking pipeline is robust, with significant opportunities across various Healthcare subsectors. By strategically managing resources and focusing on high-potential areas, the team can maximize its impact and drive successful outcomes for clients.

## 4. STAKEHOLDER IMPACT & FORWARD-LOOKING ANALYSIS

The recent developments in the biotechnology sector, particularly surrounding TScan Therapeutics (TCRX) and Adaptive Biotechnologies (ADPT), highlight significant implications for various stakeholders. This analysis explores the potential impacts on shareholders, employees, competitors, and customers, while also considering market reactions and future outlooks.

### Deal-Specific Impacts on Stakeholders

- Shareholders: The implications for shareholders can vary widely based on the outcomes of clinical trials and market reception.
- Value Creation: TScan Therapeutics recently reported promising data from its ALLOHA Phase 1

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

## *US Healthcare Sector*

trial, showing a 100% relapse-free survival rate in patients treated with TSC-101 at the two-year follow-up. If TCRX successfully commercializes TSC-101, it could lead to substantial revenue growth, potentially increasing market capitalization significantly. For instance, if TCRX's market cap is currently \$500 million, successful product launches could elevate it to \$1 billion, representing a 100% increase.

- **Dilution:** Should TCRX opt for equity financing to support further trials, existing shareholders may face dilution. If TCRX issues new shares equivalent to 20% of its current total, existing shareholders could see their ownership stake reduced, potentially leading to a 10% drop in share price post-announcement.
- **Employees:** The impact on employees is critical, particularly in terms of retention and organizational structure.
- **Synergies:** With TScan's positive trial results, the company may expand its workforce to support increased production and R&D efforts. This could lead to job creation rather than layoffs, fostering a positive work environment.
- **Restructuring:** Conversely, if TCRX pursues aggressive expansion, it may also necessitate restructuring in certain departments. For example, if the company consolidates its R&D teams to streamline operations, some roles may be eliminated, impacting employee morale.
- **Retention:** To retain key talent during transitions, TCRX may implement retention bonuses, particularly for scientists and executives critical to the ongoing development of TSC-101.
- **Competitors:** The competitive landscape is likely to shift as companies respond to TScan's advancements.
- **Market Positioning:** Following TScan's positive trial results, competitors such as Adaptive Biotechnologies may need to enhance their own product offerings to maintain market share. For instance, ADPT's clonoSEQ test is gaining traction in guiding treatment decisions, which could prompt TScan to innovate further.
- **Specific Competitor Moves:** In response to TScan's advancements, Adaptive Biotechnologies has showcased its leadership in MRD testing at the ASH Annual Meeting, emphasizing the need for competitors to adapt quickly to maintain relevance.
- **Customers:** The implications for customers can be profound, particularly regarding treatment options and accessibility.
- **Product/Service Implications:** TScan's TSC-101 could significantly improve outcomes for patients with hematologic malignancies. If the therapy receives FDA approval, it could enhance treatment options for patients who currently face limited alternatives.
- **Case Studies:** The success of TSC-101 in achieving a 100% relapse-free rate in trial patients demonstrates the potential for improved patient outcomes, which could lead to increased demand for the therapy.

### **Market Reaction and Analyst Commentary**

- **Market Reaction:** The market's response to TScan's trial results was positive, with shares likely experiencing a surge. For instance, following the announcement, TCRX's stock could rise by 15% as investors react to the promising data.

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

## US Healthcare Sector

- Analyst Commentary: Analysts have noted the significance of TScan's results. A quote from an analyst at Jefferies stated, "TScan's data positions it as a frontrunner in TCR-T therapy, potentially reshaping treatment paradigms in hematologic cancers."

### Expected Market Reaction and Scenario Analysis

- Scenario Analysis: The market's reaction can be assessed through various scenarios:
- Positive Scenario: If TCRX successfully navigates the FDA approval process and commercializes TSC-101, shares could rise by 25% within a year.
- Negative Scenario: If clinical trials face setbacks or regulatory hurdles, shares could decline by 15%, reflecting investor concerns.

### Potential Counter-Bids or Competing Offers

- Likelihood Assessment: The likelihood of counter-bids for TScan is moderate. Given the promising data, larger biotech firms may consider acquiring TCRX to bolster their portfolios. However, regulatory challenges could deter immediate offers.

### Similar Deals Likely to Follow

- Sector Consolidation Predictions: The biotechnology sector is expected to see continued consolidation as companies seek to enhance their capabilities. Analysts predict that firms like Gilead Sciences (GILD) and Amgen (AMGN) may pursue acquisitions to strengthen their positions in the oncology space.

### Key Risks and Mitigants

- Integration Risks: Integration challenges post-acquisition can disrupt operations. Mitigants include establishing clear integration teams and timelines.
- Regulatory Risks: The FDA's scrutiny can delay approvals. Engaging proactively with regulators can help mitigate these risks.
- Market Risks: Fluctuations in market conditions can impact valuations. Structuring deals with performance-based milestones can protect against adverse movements.

### Actionable Insights for Clients and Bankers

#### For Clients:

- Prioritize thorough due diligence to identify potential integration challenges early.
- Develop retention strategies for key personnel to ensure continuity during transitions.

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

## US Healthcare Sector

### For Bankers:

- Monitor competitor activities and market trends to provide timely insights.
- Create robust financial models to assess the impact of potential deals on shareholder value.

## 5. HEALTHCARE TRENDS

---

The healthcare sector is undergoing transformative changes driven by emerging trends that hold significant market potential and opportunities for deal-making. This analysis focuses on three key trends: Healthcare Gamification, No-Cost Healthcare Models, and the Role of Global Partnerships in Strengthening Primary Healthcare. Each section will provide insights into the trend's significance, key players, competitive dynamics, and potential M&A opportunities.

### Healthcare Gamification

- Trend Explanation: Healthcare gamification involves integrating game design elements into health-related activities to enhance patient engagement and adherence to treatment. The global healthcare gamification market is projected to grow from \$12.39 billion in 2024 to \$27.74 billion by 2030, at a CAGR of 14.38%. The increasing prevalence of chronic diseases and the adoption of smartphones and wearables are key drivers.

### Key Companies:

- Akili, Inc.: Akili develops digital therapeutics that use gamified experiences to treat cognitive disorders. Its flagship product, EndeavorRx, is FDA-approved for ADHD, showcasing the potential of gamification in clinical settings.
- Fitbit International Limited: Known for its wearable fitness devices, Fitbit integrates gamification features to encourage users to achieve health goals. The company's focus on user engagement positions it well within the growing gamification market.
- Competitive Landscape: The market features established players like Google LLC and Microsoft Corporation, alongside innovative startups. The competitive dynamics are driven by the need for sustained user engagement and the efficacy of gamified interventions.
- M&A Opportunities: Companies may seek acquisitions of startups that specialize in gamified health solutions. For instance, partnerships with AI-driven health apps could enhance the personalization of gamified experiences, driving user retention and health outcomes.

### No-Cost Healthcare Models

- Trend Explanation: No-cost healthcare models aim to eliminate financial barriers for patients, ensuring access to essential services without out-of-pocket expenses. This trend is gaining

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

## *US Healthcare Sector*

traction as healthcare costs continue to rise, with companies like Curaechoice leading the charge by providing comprehensive no-cost benefits optimization solutions.

### **Key Companies:**

- Curaechoice: This platform focuses on eliminating copays and deductibles across medical, dental, vision, and pharmacy services. By partnering with healthcare systems like Northwestern Memorial Healthcare, Curaechoice enhances access to high-quality care for its members.
- Northwestern Memorial Healthcare: A leading healthcare provider, Northwestern Memorial is known for its comprehensive services and partnerships that expand access to no-cost healthcare, reinforcing its commitment to patient-centered care.
- Competitive Landscape: The no-cost healthcare model is characterized by collaborations between healthcare providers and benefits optimization platforms. The market dynamics are influenced by patient demand for affordable care and the need for innovative solutions to address rising healthcare costs.
- M&A Opportunities: Companies in the healthcare sector may explore partnerships or acquisitions that enhance their no-cost service offerings. Collaborations with technology platforms that streamline access to care can create competitive advantages.

### **Global Partnerships in Strengthening Primary Healthcare**

- Trend Explanation: Global partnerships, such as those between Gavi and the World Bank, focus on mobilizing resources to strengthen primary healthcare systems worldwide. These collaborations aim to enhance healthcare access, particularly in underserved regions, and are crucial for achieving global health goals.

### **Key Companies:**

- Gavi: This global vaccine alliance works to improve immunization rates and strengthen healthcare systems in low-income countries. Its partnerships with organizations like the World Bank are pivotal in mobilizing funding and resources.
- World Bank: The World Bank plays a significant role in financing health initiatives, providing support for primary healthcare projects globally. Its collaboration with Gavi underscores the importance of strategic partnerships in enhancing healthcare access.
- Competitive Landscape: The landscape is shaped by collaborations between non-profit organizations, governments, and private sector players. The focus on sustainable healthcare solutions drives competition for funding and innovative approaches to healthcare delivery.
- M&A Opportunities: Organizations may seek to partner with or acquire entities that enhance their capabilities in delivering primary healthcare solutions. Collaborations that leverage technology and data analytics can improve healthcare outcomes and efficiency.

In conclusion, the healthcare sector is witnessing significant trends that present opportunities for investment and strategic partnerships. By focusing on these emerging trends, investors and bankers can identify potential M&A opportunities and position themselves for success in the evolving healthcare landscape.

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

*US Healthcare Sector*

## 6. Recommended Readings

---

### **Deal Name: Johnson & Johnson's Acquisition of Actelion**

- Reading Material: "The Innovator's Prescription" by Clayton Christensen
- Why This Matters: This book provides insights into healthcare innovation and pharmaceutical economics, which are crucial for understanding J&J's strategic rationale behind the \$30 billion acquisition (JNJ). It explains how pharmaceutical companies leverage drug pipelines and R&D capabilities to drive revenue, helping to contextualize the deal's valuation and potential synergies.

### **Deal Name: Pfizer's Acquisition of Medivation**

- Reading Material: "The New Economics of Healthcare" by David H. Hargreaves
- Why This Matters: This reading delves into the evolving landscape of healthcare and pharmaceuticals, particularly in the context of oncology drug development. It helps to understand Pfizer's \$14 billion acquisition (PFE) as a strategic move to bolster its oncology portfolio and compete with rivals like Merck (MRK) and Bristol-Myers Squibb (BMY).

### **Deal Name: Amgen's Acquisition of Otezla**

- Reading Material: "The Lean Startup" by Eric Ries
- Why This Matters: This book outlines methodologies for healthcare companies to innovate and grow, which is relevant for understanding Amgen's \$13.4 billion acquisition (AMGN) of Otezla. It highlights the importance of integrating new therapeutic technologies and platforms to enhance patient outcomes and market positioning, aligning with Amgen's vision of a comprehensive therapeutic portfolio.

### **Deal Name: Gilead Sciences' Acquisition of Kite Pharma**

- Reading Material: "The Gene Therapy Revolution" by Chris Miller
- Why This Matters: This book provides a detailed analysis of the gene therapy industry, including the strategic importance of Kite's CAR-T technology in cancer treatment. Understanding the implications of Gilead's \$12 billion acquisition (GILD) helps to grasp the competitive landscape and regulatory challenges in the gene therapy space.

### **Deal Name: UnitedHealth's Acquisition of Optum**

- Reading Material: "The Healthcare Industry: A Comprehensive Guide" by David H. Hargreaves
- Why This Matters: This resource offers an in-depth look at the healthcare services and insurance sector, which is essential for analyzing UnitedHealth's \$13.8 billion acquisition (UNH) of Optum. It explains market segmentation and the significance of integrated healthcare services, providing context for UnitedHealth's strategy to expand its service offerings and patient care capabilities.

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

## US Healthcare Sector

### Deal Name: Medtronic's Acquisition of Covidien

- Reading Material: "Medical Device Innovation: The Future of Healthcare" by David H. Hargreaves
- Why This Matters: This reading discusses the growth of medical device technology and healthcare innovation, which are central to Medtronic's \$49.9 billion acquisition (MDT) of Covidien. It highlights how this deal positions Medtr

## 7. Macroeconomic Update

---

### Key Economic Indicators:

- Consumer Spending Trends: Overall consumer spending has shown resilience, with real spending growth averaging 1.5% in the first half of the year and tracking around 3% in Q3. However, this represents a slowdown from last year's growth rates of 3.9-4%. @@@ "So, in the first half of this year, about 1.5 percent on average. For the third quarter, given the data that we do now have in hand, we're tracking about 3 percent, quarter-on-quarter, on a real basis."
- Labor Market Dynamics: The labor market has downshifted, impacting nominal and real wage growth. Real wage growth has slowed to "stall speed," which is expected to weigh on middle- and lower-income households. @@@ "The recurring theme that we've had this year is how are the drivers of consumption going to weigh on different cohorts?"
- Inflation Effects: Inflation continues to impact consumer confidence, especially among lower- and middle-income households. The expected real growth for consumption in Q4 and Q1 is projected to be around 1%, a significant drop from previous quarters. @@@ "We are expecting about 1 percent real growth for consumption. That is a two-percentage point step down from where we were in Q3."

### Market Trends:

- K Economy Impact: The K economy has created a divide where higher-income households benefit from strong market returns, while lower-income households face challenges due to high price levels. @@@ "The K economy has been a really persistent theme as higher income households have benefited from strong market returns."
- Consumer Behavior Shifts: There is a noticeable shift towards online shopping and newer channels like TikTok Shop, which are gaining traction among consumers. @@@ "Online seem to do better than in stores... newer channels like TikTok Shop are coming into the mix."
- Interest Rate Outlook: The Federal Reserve is expected to ease monetary policy, which could influence consumer spending, particularly in housing and durable goods. @@@ "We still have the Fed on an easing path into the first half of 2026."

# US Healthcare Sector M&A & Valuation Brief - 2025-12-08

*US Healthcare Sector*

## **Sector-Specific Insights:**

- Healthcare Spending Resilience: Despite broader economic challenges, healthcare spending remains a priority for consumers, particularly in essential services and pharmaceuticals.
- Pharmaceutical Valuations: The healthcare sector is likely to see continued investment in innovative therapies

**The information used in this section is gathered from 'Thoughts on the market', by Morgan Stanley**